OD6 Metals Limited (ASX: OD6) commenced Phase 2 drilling at the 100%-owned Gulf Creek Copper Project (NSW), advancing the first modern program over a historically high-grade VMS system. The campaign targets along-strike repeats of the Gulf Creek mine stratigraphy where magnetics, jaspilite exhalites, and surface pathfinders coincide (Figure 1).

Race Oncology Limited (ASX: RAC) has reported a pivotal mechanistic discovery: its lead molecule (E,E)-bisantrene (RCDS1) primarily exerts anticancer activity by binding and stabilising G-quadruplex (G4) structures in DNA and RNA—not via an anthracycline-like pathway. The company positions this as a step-change for clinical strategy, biomarker development, and partnering.

Echo IQ Limited (ASX: EIQ) has delivered a concise update showing rising clinical usage for EchoSolv™ AS, clear progress on EchoSolv™ HF’s FDA pathway, and expanding commercial channels in the US and Europe. The near-term catalysts are anchored in actual hospital integrations, validation work nearing completion, and newly appointed US key opinion leaders guiding adoption.

The Calmer Co. International Limited (ASX: CCO) has reported the strongest quarter in its history with Q1 FY26 sales of $2.4 million, up 26% on Q4 FY25 ($1.9m). Growth was broad-based across Australian retail, the USA, and B2B channels, with additional funding commitments to support inventory and expansion.

DevEx Resources Limited (ASX: DEV) is leaning hard into the Northern Territory uranium thesis with a 2025 program that moves from mapping to gravity-constrained drilling across Nabarlek’s Big Radon and KP prospects (Figure 1)—two kilometre-scale radon anomalies now tied to fault architecture by new ground gravity. Heritage clearances are being finalised and the NT Government has tipped in $160k to co-fund the maiden holes, a tidy endorsement at this stage.

Yandal Resources Ltd (ASX: YRL) has confirmed a new gold discovery at the Arrakis Prospect within the Caladan target area of the Ironstone Well–Barwidgee Project — a major milestone that de-risks exploration and advances the project (Figure 1). With 54m @ 1.2g/t Au from fresh rock, including 8m @ 4.7g/t Au, the result highlights scale and continuity over more than 2.2km of strike.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has taken a major step toward establishing a commercial presence in the Australian and New Zealand markets. The company has entered into an exclusive licensing agreement with global pharmaceutical manufacturer Sakar Healthcare Limited (NSE: SAKAR, BSE: 538377) (Figure 1) to launch five oncology medicines across the region.

AuMEGA Metals Limited (ASX: AAM) has reported a standout result from its July airborne time-domain EM survey over Cape Ray: the work both maps known mineralisation at Central Zone and—critically—defines a large, previously untested conductor just 500 m to the southeast that mirrors Central Zone’s geophysical signature. With a fully funded drilling program slated for Q4 2025, the discovery pipeline at Cape Ray continues to expand.

Terra Critical Minerals Limited (ASX: T92) has confirmed a new high-grade silver discovery at the Silent Grove Prospect within its 100%-owned Mole River Project in New South Wales (Figure 1). This update represents an important step forward in unlocking the polymetallic potential of the Mole Granite district, an area already known for tin, tungsten, and silver-rich systems.

DY6 Metals Ltd (ASX: DY6) has delivered a practical operational update across its Malawian projects (Figure 1), completing follow-up surface sampling at Tundulu and commencing a new grid-based program at Machinga. The work targets high-value mineralisation in gallium (Ga), rare earth elements (REEs), niobium (Nb) and phosphate, with assays in preparation for SGS Randfontein.

Kaiser Reef Limited (ASX: KAU) has marked its first full quarter since acquiring the Henty Gold Mine, with reconciled production reported for 1 July–30 September 2025. Alongside the steadying of Henty as the core asset, the quarter featured renewed activity at Maldon and a strategic transition at A1, setting a clearer operational footing across the portfolio.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.